Checking Vaccine Immune Responses After CAR-T Therapy in Myeloma and Lymphoma
Observes whether vaccine protection is reduced in adults with myeloma or lymphoma after CAR-T.
Plain-language title generated from the registry record
Registry title: Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Key facts
- Where
- Portland, United StatesSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with multiple myeloma or certain non-Hodgkin lymphomas who are about to have CAR-T therapy. It studies how vaccine protection changes afterwards.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Confirmed multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, or primary mediastinal B cell lymphoma. Any number of earlier treatments is allowed.
- Earlier treatment
- Must have been vaccinated before against common vaccine-preventable diseases. The doctor must approve CAR-T therapy, with preparation planned within the next 90 days. The doctor must approve revaccination against Streptococcus pneumoniae or tetanus.
Main reasons for not taking part
- Ongoing use of immune-suppressing drugs, or plans for them that would affect the study results
- Uncontrolled other illness, such as a body-wide infection, symptomatic heart failure or unstable angina
- Mental illness or social situations that would limit following the study requirements
Read by machine on 12 November 2026.
Where in United States
- OHSU Knight Cancer InstitutePortland, United StatesContact: Amrita DesaiTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- OHSU Knight Cancer Institute
- Trial code
- NCT06784167
- Record updated
- 23 September 2026
- Original description
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.Read full original descriptionShow less
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkins Lymphoma Post CAR-T Treatment
This study evaluates immune responses after CAR-T therapy to find out if CAR-T therapy reduces the effectiveness of the vaccines (vaccine immunity) against diseases such as measles, mumps and rubella, among others in patients with multiple myeloma and non-Hodgkin lymphoma.
Inclusion: * Willingness to provide written informed consent before any study-specific procedures or activities are performed; Age ≥ 18 years of age, at the time of consent; Documented, histologically or cytologically confirmed diagnosis of multiple myeloma (MM), diffuse large B cell lymphoma (DLBCL),follicular lymphoma (FL), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL), or primary mediastinal B cell lymphoma (PMBL). All number of prior lines of therapy are allowed; History of prior vaccination against common VPD; Approved by managing physician for CAR-T therapy, with preparative conditioning planned within the next 90 days; Approved by managing physician for revaccination against Streptococcus pneumoniae or tetanus.
Exclusion: * Ongoing use of immunosuppressive agents or plans for immunosuppressive therapy that would interfere with interpretation of study endpoints; Uncontrolled, intercurrent illness including, but not limited to, systemic infection, symptomatic congestive heart failure, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements or make the study procedures unadvisable.